Cell-Penetrating Peptides for Muscular Dystrophy Treatment

USPTO published patent application US20260091120A1 disclosing novel cell-penetrating peptide compositions and methods for treating muscular dystrophy, particularly Duchenne muscular dystrophy. The claimed invention features peptides with a first hydrophobic domain at the C-terminus and a second hydrophobic domain at the N-terminus, which may be conjugated to therapeutic molecules. Inventors include Matthew Wood, Samir El Andaloussi, Graham McClorey, and others. The application covers therapeutic uses of these peptides and conjugates in methods of treatment.

No immediate compliance action is required. This is a patent application publication, not a granted patent. Pharmaceutical companies, biotech firms, and researchers developing therapies for muscular dystrophy or genetic disorders should monitor the prosecution of this application, as its eventual grant could impact freedom-to-operate for competing therapeutic peptide technologies. The filing date of October 21, 2025, establishes priority for the disclosed compositions.